Probi recruits new CEO
Probi has recruited Peter Nählstedt as its new CEO. Peter Nählstedt has extensive experience from the international Life Science industry through various executive positions involving strategy, marketing and sales at GE Healthcare Life Science. Peter Nählstedt joins Probi from Trelleborg Marine Systems where he has been responsible for operations in Europe, South America and North Africa. Nählstedt will assume his new position on 7 January 2014. Gun-Britt Fransson, who has been Acting CEO since the end of May 2013, will continue in her role as Vice President Research and Development and member of Probi’s management group.
In 2010, Peter Nählstedt was recruited to Trelleborg Marine Systems to take responsibility for operations in Europe, South America and North Africa. Prior to this, he spent eight years at GE Healthcare, where he was General Manager Sales and Marketing for Bioprocess in North America between 2007 and 2010 and before that Strategic Marketing Director. During his time at GE Healthcare, Peter held various global executive positions with a focus on strategy, marketing and sales. He also worked with sales and marketing at Sigma Aldrich, a leading manufacturer of high technological products for life science research.
“With the recruitment of Peter Nählstedt, we gain an individual with a solid strategic and international business background which, combined with Probi’s strong management team, will propel Probi into the next phase of its development in the form of continued expansion and further broadening of the operation, primarily in the international market,” says Per Lundin, Chairman of the Board of Probi.
“Probi is currently in a phase of expansion with investments in Research and Development and in continued growth. The company has an excellent base for expansion through its clinically documented probiotic products and patented technology. I look forward to working with new distribution solutions and proprietary brands, as well as intensive business development in selected markets, such as the US, Eastern Europe and Asia,” says Peter Nählstedt.
This information is such that Probi AB is required to disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.
FOR MORE INFORMATION, PLEASE CONTACT:
Per Lundin, Chairman of the Board, Tel: +46 (0)705-741171, e-mail: per.lundin@transit.se
Peter Nählstedt, forthcoming CEO, Tel: +46 (0)706-848386
ABOUT PROBI
Probi is a leading player in probiotic research and the development of efficient and well-documented probiotics. Its research areas include: gastrointestinal tracts, immune system, metabolic syndrome and stress and recovery. Probi’s customers are leading companies in the Functional Food and Consumer Healthcare segments. Total income for 2012 totalled MSEK 100.4. Probi’s share is listed on the NASDAQ OMX Stockholm, Small Cap. Probi has approximately 5,000 shareholders. Read more at på www.probi.se.
Tags:
